PART-3
We Believe That GenoMed Is On The Verge Of Making A Series Of
Discoveries Concerning Which Genes Cause Major Illnesses & Diseases
In our opinion, the scientific data which GenoMed's researchers and
others have discovered through the past eight years of clinical-oriented
studies provide more than enough evidence to justify GMED’s belief that
it has identified a class of SNPs that appear to cause most common
diseases (www.genomedics.com/index..advantages)
We believe that GMED is on the right track, and, in the not too distant
future, will be able to identify the causes of common diseases at the
genetic level.
By knowing where to look for disease-causing variations in genes (in
the "regulatory regions" of genes), GenoMed
on-track to find body’s "on / off" switches. GMED’s research methods
are novel (actually, everyone else is taking a far different approach).
Lastly, GenoMed is compiling a huge database of DNA samples from actual
patients around the world and is using ultra-high throughput genotyping
in the production of their data.
There’s going to be a huge payday for the first company to identify the
gene (or group of genes) that triggers a major illness like diabetes or
cancer…
In closing, what will this mean for the average person?
GenoMed hopes to discover a comprehensive list of disease-causing genes
so that doctors can predict with reasonable confidence what diseases a
person may experience during their lifetime. Drugs developed and
directed specifically against these disease-causing genes are expected to
halt these diseases in their tracks.
As Dr. Moskowitz has conclusively proven with the ACE gene, knowledge
of disease-causing genes can also help people with already-established
diseases.
Early detection will allow doctors to halt the disease process at an
early-enough stage so that we might even be able to prevent the disease
from occurring. Keep in mind that Dr. Moskowitz has already proven that
this approach works - witness the great success that he has had with
patients suffering from kidney disease, poor circulation, and emphysema
by prescribing an effective dose of ACE-inhibitor medications...
GenoMed’s goal is nothing short of a medical revolution: they aim to
change the way medicine is practiced. Instead of waiting for symptoms to
develop, doctors will soon be able to diagnose disease before any signs
are visible.
Just as Microsoft brought us the Age of Personal Computing, GenoMed
intends to be a leader in the Era of Preventive Molecular Medicine.
Sources of Additional Information
GenoMed’s "revolutionary genomics research" was recently profiled in
the St. Louis Business Journal - the complete story can be found at
(http://www.stlouis.bcentral.com/stlouis/stories/2001/11/26/d... <http://www.stlouis.bcentral.com/stlouis/stories/2001/11/26/daily39.html>).
GenoMed’s recent press releases can be accessed at the company’s
website: <http://www.genomedics.com/index…press>.
GMED
GMED anticipates that it will file a Form 10-SB with the U.S.
Securities & Exchange Commission by January 2002; the complete filing will be
available on-line at <http://www.sec.gov/>. Information on the law firm handling
GMED’s filings can be found at: <http://www.hldpa.com>
Investors and other interested parties are also encouraged to visit the
Company’s web site (<http://www.genomedics.com>) and/or contact Craig
Hall @ (941) 366-6677 (e-mail: chall@floridafunds.com).
Richard Kranitz Joins GenoMed, Inc. as a Member of its Board of
Directors and as Corporate Secretary
SARASOTA, Fla., Dec 13, 2001 (BUSINESS WIRE) -- GenoMed Inc. ("the
Company" or "GenoMed") (Pink Sheets:GMED), a St. Louis based medical
genomics biotechnology company, announced today that Richard Kranitz has
accepted a position as a member of the Company's Board of Directors and as
Corporate Secretary.
Richard Kranitz, an attorney in private practice since 1970, is a 1969
graduate of the University of Wisconsin Law School and served for a
year as an assistant to a federal judge. During the past 30 years he has
served as a director of a number of private companies, and professional,
civic, and charitable organizations. Since 1990, Mr. Kranitz has been a
director of the Grafton State Bank, a subsidiary of Merchants &
Manufacturers Bancorporation (symbol:MMBI). He has also served as a director
of, among other public companies, Harp & Eagle, Ltd. (symbol:HARP) and
Mentor Capital Consultants, Inc. (symbol:MCAP). Mr. Kranitz has served
for a number of years as a director of the Mental Health of Ozaukee
County, Inc., a non-profit organization promoting mental health and care
for the mentally ill.
Mr. Kranitz's law firm concentrates in business and securities matters,
including mergers & acquisitions, private and public securities
offerings, investment funds, and corporate organizational matters. The firm's
clientele is located around the United States as well as several
foreign countries. |
